Linear IgA bullous dermatosis protracted by vancomycin-loaded bone cement

Nathan Nartker, MD,a Natalie Kudlak, DO,b and David Crowe, MDb
Detroit, Michigan, and Cleveland, Ohio

Key words: antibiotic-loaded bone cement; bullous dermatosis; linear IgA; vancomycin.

INTRODUCTION
Linear IgA bullous dermatosis (LABD) is a subepidermal, vesiculobullous eruption that can be drug induced, often by vancomycin.1 We describe a rare case of an 80-year-old woman with vancomycin-induced LABD whose disease continued to progress despite drug cessation, likely attributable to continued drug elution from vancomycin-loaded bone cement from a recent shoulder arthroplasty revision.

CASE REPORT
An 80-year-old woman, with a medical history significant for moderate chronic kidney disease (stage IIIa), hypertension, atrial fibrillation, and numerous orthopedic procedures, underwent a left total shoulder arthroplasty revision in the setting of a Staphylococcus epidermidis joint infection. The procedure entailed prosthesis explantation, placement of a vancomycin-loaded cement joint spacer, and intravenous vancomycin and rifampin antibiotic therapy. Two weeks after the procedure, she presented to our clinic with an abrupt onset of pruritic, burning, painful skin lesions accompanied by odynophagia, vulvar pain, and increased lacrimation. She denied experiencing intolerance to these antibiotics with prior use, recent exposure to other medications or allergens, or previous skin diseases. Physical examination found scattered tense vesiculobullae with negative Nikolsky and Asboe-Hansen signs, erosions and erythematous patches favoring the right arm (Fig 1, A) and left shoulder, and oral erosions. Because of concern for a drug hypersensitivity contributing to the patient’s symptoms, all intravenous antibiotics were discontinued, and biopsy specimens were obtained from the right arm for pathologic examination.

Laboratory evaluations found a negative varicella zoster virus direct fluorescent antibody stain, and a basic metabolic panel was significant for stable moderate chronic kidney disease, unchanged from baseline before vancomycin initiation. Sections from a punch biopsy of the right arm showed a dense, subepidermal infiltrate composed almost exclusively of neutrophils (Fig 1, B), and portions showed early subepidermal vesicle formation (Fig 1, C). Direct immunofluorescence displayed linear IgA deposition in the basement membrane zone, and a diagnosis of LABD was made.

Five days after the discontinuation of intravenous vancomycin, despite 4 days of systemic corticosteroid therapy (60 mg [0.6 mg/kg] prednisone daily), our patient’s vesicular eruption continued to evolve. She reported intense pruritus and burning pain causing distressing insomnia. A repeat physical examination found widespread progression of disease with additional lesions on her shoulders and arms, which demonstrated the crown of jewels or string of pearls sign (Fig 1, D) classically associated with LABD. Scattered superficial erosions were appreciated on the palate, buccal, and vulvar mucosa. Although expected to be undetectable given the time since drug cessation, serum vancomycin levels were obtained and remained elevated at 5.7 μg/mL, suggesting continued release from the joint spacer, as the drug should have cleared in roughly 2 days based on renally corrected drug elimination calculations. Treatment was escalated to 80 mg prednisone daily (0.8 mg/kg) with triamcinolone 0.1% ointment.
applied twice daily and hydroxyzine, 25 mg once
daily, as needed for symptom management.

Vesicle formation ceased 10 days after intravenous
vancomycin discontinuation, and systemic steroids
were tapered. Two weeks after presentation, ero-
sions were healing appropriately, and vancomycin
levels were less than 3.5 \( \mu g/mL \). Serum vancomycin
levels were undetectable at 6 weeks, and disease has
since remained quiescent with cessation of steroids.

DISCUSSION

LABD is relatively rare, with an estimated inci-
dence of 0.6 per 100,000 adults. It typically affects
adults over the age of 60 with a slight female
predilection. Classically, LABD presents as annular
erythema with a ring of tense vesicles or bullae
distributed symmetrically on the trunk and extrem-
ities; however, the morphology can vary from
expanding annular plaques to tense bullae
mimicking bullous pemphigoid, and even morbilli-
form and epidermal necrolysis-like eruptions as
rarely reported in cases of vancomycin-associated
LABD.² Mucous membranes are affected in 40% of
patients.³

An association between LABD and drug expo-
sure, most commonly vancomycin, is well docu-
mented.¹,³ Acting as a hapten, it is thought that
vancomycin stimulates an immune response with
exaggerated IgA production in susceptible individ-
uals, resulting in a cutaneous eruption, on average,
8.2 days after drug initiation.³ Direct immuno-
fluorescence of perilesional skin, the gold standard for
diagnosing LABD, shows characteristic deposition of
IgA in a linear distribution along the basement
membrane zone with neutrophilic inflammation.¹,³
Drug cessation is the mainstay of treatment, with
new lesion formation typically resolving 1 to 3 days
after discontinuation. For recalcitrant disease, as

Fig 1. LABD protracted by vancomycin-loaded bone cement. A, Initial clinical presentation
with vesicular eruption on right arm. B, Histopathology shows a dense subepidermal infiltrate
composed almost exclusively of neutrophils. C, Histopathology shows early blister formation.
D, Five days after initial presentation, with clinical progression and classic crown of jewels or
string of pearls on right arm. (B and C, Hematoxylin-eosin stain; original magnifications: B,
×10; C, ×4.)
seen with our patient, systemic corticosteroids or dapsone may be indicated.3

One of the most commonly reported complications of reverse total shoulder replacement is infection.4 Treatment of a periprosthetic joint infection involves a 2-stage revision, whereby the joint is explanted and a cement spacer loaded with high-dose antibiotics, typically aminoglycosides and/or vancomycin, is incorporated until subsequent reimplantation.5 Through elution of antibiotics into the joint fluid, these cement spacers ensure high local antibiotic concentrations in the joint space and result in significantly reduced infection rates.1

Unfortunately, however, systemic absorption of these antibiotics is common. A prospective study found absorption from vancomycin-loaded cement spacers to peak within hours of placement and remain detectable (range, 1.8–14.38 μg/mL) for up to 8 weeks after placement, even in patients who did not receive simultaneous intravenous vancomycin therapy.4

Systemic toxicity from vancomycin-loaded cement spacers is rarely reported in the literature, with acute kidney injury being the most common adverse effect, followed by rare hepatic failure and bone marrow depression.6 There are few reports of vancomycin-loaded cement spacers being associated with adverse dermatologic events, including an unspecified rash and a diffuse desquamating rash after implantation of vancomycin-loaded cement.7,8 Other reports describe adverse dermatologic effects after exposure to vancomycin via systemic and vancomycin-loaded cement spacers simultaneously, including 2 cases of hypersensitivity syndrome/drug reaction with eosinophilia and systemic symptoms, as well as a nonspecified drug eruption after arthroplasty revision.9,10 To our knowledge, no associations between vancomycin-loaded bone cement and LABD have been reported in the literature.

We report an unusual case of a patient with vancomycin-induced LABD whose symptoms unexpectedly evolved despite intravenous vancomycin cessation. Continued systemic absorption of vancomycin from antibiotic-loaded bone cement, along with decreased renal clearance secondary to moderate CKD may have contributed to the protracted course of our patient’s disease. Careful consideration should be made when identifying a source for LABD and when considering the complications of antibiotic-impregnated cement spacers.

The authors thank the patient for granting permission to share this information. We also thank Dr. Stephen Somach and the dermatopathology team at MetroHealth Medical Center, Cleveland, OH, for the histopathologic diagnoses. They received no compensation for their contributions.

REFERENCES
1. Kuechle MK, Stegemeier E, Maynard B, Gibson LE, Leiferman KM, Peters MS. Drug-induced linear IgA bullous dermatosis: report of six cases and review of the literature. J Am Acad Dermatol. 1994;30(2 Pt 1):187-192.
2. Mobacken H, Kastrup W, Ljunghall K, et al. Linear IgA dermatosis: a study of ten adult patients. Acta Dermato-Venereol. 1983;63(2):123-128.
3. Nousari HC, Kimyai-Asadi A, Caeiro JP, Anhalt GJ. Clinical, demographic, and immunohistologic features of vancomycin-induced linear IgA bullous disease of the skin. Report of 2 cases and review of the literature. Medicine. 1999;78(1):1-8.
4. Nowinski RJ, Gillespie RJ, Shishani Y, Cohen B, Walch G, Gobezie R. Antibiotic-loaded bone cement reduces deep infection rates for primary reverse total shoulder arthroplasty: a retrospective, cohort study of 501 shoulders. J Shoulder Elbow Surg. 2012;21(3):324-328.
5. Edelstein AI, Okroj KT, Rogers T, Della Valle CJ, Sporer SM. Systemic absorption of antibiotics from antibiotic-loaded cement spacers for the treatment of periprosthetic joint infection. J Arthroplasty. 2018;33(3):835-839.
6. Anagnostakos K. Therapeutic use of antibiotic-loaded bone cement in the treatment of hip and knee joint infections. J B Joint Infect. 2017;2(1):29-37.
7. Williams B, Hanson A, Sha B. Diffuse desquamating rash following exposure to vancomycin-impregnated bone cement. Ann Pharmacother. 2014;48(8):1061-1065.
8. Wentworth SJ, Masri BA, Duncan CP, Southworth CB. Hip prosthesis of antibiotic-loaded acrylic cement for the treatment of infections following total hip arthroplasty. J Bone Joint Surg Am. 2002;84-A(Suppl 2):123-128.
9. Guner MD, Tuncbilek S, Akan B, Caliskan-Kartal A. Two cases with HSS/DRESS syndrome developing after prosthetic joint surgery: does vancomycin-laden bone cement play a role in this syndrome? BMJ Case Rep 2015;2015.
10. Xu S, Ponce BA, Pavlidakey PG, Brabston EW 3rd. Drug eruption secondary to vancomycin-laden spacer in the shoulder: a case report. J Shoulder Elbow Surg. 2016;25(8):e236-e240.